Rezolute, Inc. is a clinical stage biopharmaceutical company based in California, USA. It specializes in developing transformative therapies for metabolic diseases associated with chronic glucose imbalance. Its lead product candidate, RZ358, is currently in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, while RZ402 is in Phase 1 clinical trial for treating diabetic macular edema.